Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEAL: Switching to Tenofovir-Emtricitabine or Abacavir-Lamivudine in HIV
NCT00192634Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Dec 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abacavir + lamivudine and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Kirby Institute. Primary endpoint: Virological Failure at 48 weeks. Started Dec 2005; status: completed.
02
Drugs
abacavir + lamivudineemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00192634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192634.